Artivion, Inc. (AORT)
NYSE: AORT · Surgical & Medical Instruments & Apparatus · Kennesaw, GA · filing with the SEC since 1996
Grade6.0
◀ Past 5.9● Present 6.5▶ Future 5.4
Who owns Artivion, Inc.
As filed with the SECHolders of 5% or more
2
Blackrock, Inc. holds 14.7% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
15
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 12.7% in Oct 17, 2025
Nomura Asset Management International Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.01 par value · 5.5% in Feb 17, 2026
Morgan Stanley
SCHEDULE 13G/A · filed Nov 7, 2025 · Common Stock · reported falling below 5%
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.01 par value · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · reported falling below 5%, from 5.4% in Aug 6, 2025
Juniper Investment Company, LLC
SCHEDULE 13D/A · filed Aug 12, 2025 · Common Stock, $0.01 par value · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
Macquarie Group Limited
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Shares · reported falling below 5%, from 5.26% in Nov 13, 2025
What AORT reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Artivion Inc. and Starch Medical Inc.
An entity · legal entity · owns, named in the 10-K filed Feb 18, 2026
Starch Medical Inc.
An entity · legal entity · owns, named in the 10-K filed Feb 18, 2026
Ascyrus Medical Llc
A company bought · acquisition · owns, named in the 10-K filed Feb 18, 2026
38 subsidiaries in 26 countries, from the list filed with the 10-K filed Feb 18, 2026.
Insider tradesForm 4
64sales
0purchases
8sales on a scheduled plan
8people selling
$20.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mackin James P | President & CEO | 9 | $9.7M | 2 | 0 | $0 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | 13 | $3.4M | 0 | 0 | $0 |
| Holloway Jean F | SVP, General Counsel | 13 | $2.5M | 2 | 0 | $0 |
| Davis John E | Chief Commercial Officer | 9 | $1.7M | 2 | 0 | $0 |
| Green Andrew M | SVP, Regulatory and Quality | 6 | $1.4M | 2 | 0 | $0 |
| Horton Amy | VP, Chief Accounting Officer | 8 | $900,000 | 0 | 0 | $0 |
| Berry Lance A | EVP, COO, CFO & Treasurer | 5 | $800,000 | 0 | 0 | $0 |
| Hoff Elizabeth A | director | 1 | $200,000 | 0 | 0 | $0 |